semaglutide for lupus weight-loss-medicines-lupus-ozempic-wegovy-mounjaro-zepbound FDA Approves New Treatments: Oral

doi: 10.1111/nmo.13738 26 AnandUYiangouYAkbarAQuickTMacQuillanAFoxMet al

With the right approach, intermittent fasting can be a powerful tool for improving your health and well-being

February 16, 2025 10:00 View More GLP-1 Agonists: The Medical Revolution Beyond Weight Loss In this podcast episode, McCall McPherson, a medical professional from the Modern Thyroid Clinic, explores the benefits of GLP-1 agonists, originally developed for diabetes

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks